Calcium (Ca²⁺) signaling is fundamental to neuronal function, regulating synaptic transmission, gene expression, mitochondrial metabolism, and cellular survival. Dysregulation of calcium homeostasis is a common feature across neurodegenerative diseases, though the specific patterns and consequences differ between disorders. This page compares calcium dysregulation mechanisms across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD)[1].
Before comparing disease-specific patterns, understanding normal calcium handling is essential:
| Feature | AD | PD | ALS | FTD | HD |
|---|---|---|---|---|---|
| Primary Ca²⁺ Channel Dysfunction | VGCC, NMDA receptor | L-type Ca²⁺ channels | Voltage-gated Ca²⁺ channels | Multiple (variable) | NMDA, VGCC |
| ER Calcium Depletion | Severe | Moderate | Severe | Moderate | Severe |
| Mitochondrial Ca²⁺ Overload | Yes | Yes | Yes | Yes | Yes |
| Calpain Activation | Yes | Yes | Yes | Variable | Yes |
| Ca²⁺-dependent Proteases | Caspase-3, calpain | Calpain | Calpain | Calpain | Calpain |
| Synaptic Ca²⁺ Signaling | Impaired | Impaired | Impaired | Impaired | Impaired |
| Store-Operated Entry | Upregulated | Upregulated | Dysregulated | Variable | Upregulated |
In AD, calcium dysregulation occurs through multiple pathways[2][3]:
Amyloid-beta induced calcium dysregulation:
NMDA receptor overactivation: Excitotoxicity via excessive glutamate signaling leads to elevated intracellular Ca²⁺. Pathological activation of NMDA receptors triggers calpain activation and synaptic loss.
Voltage-gated calcium channel (VGCC) dysfunction: L-type and N-type channels show altered expression and function. Cav1.2 and Cav1.3 channels show increased expression in AD neurons, contributing to calcium overload[4].
ER calcium depletion: Store-operated calcium entry (SOCE) mechanisms are impaired. STIM1 and Orai1 expression is dysregulated in AD, leading to reduced ER calcium refilling[5].
Tau pathology: Hyperphosphorylated tau disrupts calcium signaling at synapses. Tau loss from microtubules leads to postsynaptic calcium dysregulation.
Mitochondrial calcium overload: Excessive calcium enters mitochondria through the MCU, triggering mitochondrial permeability transition pore (mPTP) opening, cytochrome c release, and apoptosis[6].
PD shows distinctive calcium patterns[7][8][9]:
L-type calcium channel vulnerability: Substantia nigra dopamine neurons express Cav1.3 channels that generate rhythmical calcium spikes during autonomous pacemaking. These L-type channels are particularly vulnerable in PD:
Mitochondrial calcium overload: Complex I dysfunction leads to impaired calcium buffering:
Alpha-synuclein interaction: αSyn aggregates disrupt ER-mitochondria contact sites (MAMs):
Dopamine metabolism: Oxidative stress from dopamine oxidation affects calcium homeostasis:
Store-operated calcium entry: SOCE is upregulated in PD models, contributing to calcium dysregulation[5:1].
ALS demonstrates severe calcium dysregulation[10]:
Motor neuron vulnerability: High basal calcium levels make motor neurons particularly susceptible:
Excitotoxicity: Glutamate-induced calcium influx through AMPA/kainate receptors:
VGCC dysfunction: Mutations in calcium channel genes (CACNA1A, CACNA1H) associated with ALS:
ER stress: Calcium release from ER triggers apoptotic pathways:
SOD1 mutations: Mutant SOD1 directly affects calcium handling:
C9orf72 expansions: Dipeptide repeat proteins affect calcium homeostasis through:
FTD shows variable calcium dysregulation depending on subtype[11]:
TDP-43 pathology: Affects calcium regulatory proteins:
GRN mutations: Progranulin deficiency alters calcium signaling:
C9orf72 expansions: Dipeptide repeats affect calcium homeostasis:
MAPT mutations: Tau mutations alter synaptic calcium signaling:
FTD subtypes show distinct patterns:
HD demonstrates severe calcium dysregulation[12]:
Mutant huntingtin: Directly interacts with calcium channels and ER:
NMDA receptor overactivation: Increased receptor density and function:
Mitochondrial calcium: Impaired buffering capacity:
ER calcium depletion: ER calcium stores are depleted:
Excitotoxicity: Leading to striatal neuron death:
Specific vulnerability of medium spiny neurons:
AD: Focus on amyloid-induced calcium dysregulation, NMDA modulation:
PD: L-type channel blockers (dihydropyridines) in clinical trials[7:1]:
ALS: Sodium channel modulators, glutamate antagonists:
FTD: Targeting tau-mediated calcium dysregulation[11:1]:
HD: NMDA receptor modulation, mitochondrial calcium stabilizers[12:1]:
| Strategy | Target | Disease | Status |
|---|---|---|---|
| L-type channel blockers | Cav1.3 | PD | Phase 3 completed |
| MCU inhibitors | Mitochondrial Ca²⁺ | AD, PD | Preclinical |
| SOCE inhibitors | STIM1/Orai1 | ALS | Preclinical |
| Calpain inhibitors | Calpain | AD, HD | Phase 1 |
| mPTP blockers | Cyclophilin D | AD, PD | Preclinical |
Calcium Dysregulation and Neurodegeneration. Cell Calcium. 2021. ↩︎
Calcium dysregulation in Alzheimer's disease: from membranes to mitochondria. Nature Reviews Neuroscience. 2007. ↩︎
Calcium Signaling in Alzheimer's Disease Pathogenesis. Nature Reviews Neuroscience. 2023. ↩︎
The role of L-type calcium channels in neurodegenerative diseases. European Journal of Pharmacology. 2019. ↩︎ ↩︎
Store-operated calcium entry in neurodegenerative diseases. Cell Calcium. 2022. ↩︎ ↩︎ ↩︎
Mitochondrial calcium handling in neurodegeneration. Cell Calcium. 2019. ↩︎ ↩︎
Calcium Channels, Parkinonism, and the Vulnerability of Dopaminergic Neurons. Nature Reviews Neurology. 2018. ↩︎ ↩︎
Calcium dysregulation and neuroinflammation in Parkinson's disease. Current Opinion in Neurobiology. 2018. ↩︎
Alpha-synuclein and calcium: An unhealthy partnership. Molecular and Cellular Neuroscience. 2017. ↩︎
Calcium Dysregulation in Amyotrophic Lateral Sclerosis. Cell Calcium. 2019. ↩︎
Calcium Dysregulation in Frontotemporal Dementia and Related Disorders. Acta Neuropathologica. 2022. ↩︎ ↩︎
Calcium Dysregulation in Huntington's Disease. Cell Calcium. 2020. ↩︎ ↩︎
Calpain activation in neurodegeneration. Nature Reviews Neurology. 2024. ↩︎